Sialidase NEU3 Contributes to the Invasiveness of Bladder Cancer

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Bladder cancer is a prevalent malignancy with limited treatment efficacy for advanced stages.
• Current treatments like neoadjuvant cisplatin (NAC)-based chemotherapy have a 50% response rate due to cisplatin resistance.
• Understanding cancer invasiveness is crucial for identifying new therapeutic targets.

Purpose of the Study:

• To investigate the role of sialidases in bladder cancer, specifically their relationship with invasive ability.
• To determine the expression and functional significance of the sialidase NEU3 in bladder cancer.
• To elucidate the signaling pathways affected by NEU3 in bladder cancer progression.

Main Methods:

• Analysis of NEU3 expression in patient bladder cancer tissues and cell lines.
• siRNA-mediated knockdown of NEU3 to assess its functional impact on invasiveness.
• Mechanistic studies to identify signaling pathways activated by NEU3, including ERK and PI3K.

Main Results:

• NEU3 sialidase is significantly overexpressed in bladder cancer tissues and cell lines.
• Knockdown of NEU3 expression reduces the invasive capacity of bladder cancer cells.
• NEU3 activation of ERK and PI3K signaling pathways was observed, contributing to cancer malignancy.

Conclusions:

• NEU3 plays a critical role in the invasiveness and malignancy of bladder cancer.
• Targeting NEU3 presents a potential novel therapeutic strategy for bladder cancer.
• Further research into NEU3 suppression could lead to improved treatments for advanced bladder cancer.